Skip to main content
. Author manuscript; available in PMC: 2014 Jul 15.
Published in final edited form as: J Immunol. 2013 Jun 10;191(2):650–659. doi: 10.4049/jimmunol.1300398

Figure 2. p38α is selectively activated in CD103+ MLN DCs and is required for these DCs to mediate iTreg generation in vitro.

Figure 2

(A) Expression of Foxp3 in OT-II T cells activated with CD103+ and CD103– MLN DCs and splenic DCs, in the presence of OVA (0.05 μg/ml), for 5 days. (B) p38 and ERK activity in CD103+ and CD103– MLN DCs and splenic DCs. Pooled samples of all 3 DC populations were used for isotype staining. (C) Expression of Foxp3 in OT-II T cells activated with WT or p38α-deficient CD103+ MLN DCs, in the presence of the indicated doses of OVA, for 5 days. (D) Expression of Foxp3 in polyclonal T cells activated with WT or p38α-deficient CD103+ MLN DCs, in the presence of the indicated doses of αCD3, for 5 days. (E) Expression of Foxp3 in OT-II T cells activated with WT or p38α-deficient CD103– MLN DCs, in the presence of the indicated doses of OVA, for 5 days. Data are representative of 2 (A, D, E, n=4 mice per group), 3 (B, n=4 mice per group) and 4 (C, n≥5 mice per group) independent experiments.

HHS Vulnerability Disclosure